Dr. Mikhail Blagosklonny, the man with a vision to cure cancer

Rapamycin which is also referred to as Sirolimus is a drug that is normally used for the prevention of organ rejection during transplants. It can also be used in the treatment of rare lung disease and coating for coronary stents. It is well known in the market as a cancer drug. The drug was first used in the treatment of fungus as an anti-fungal agent. Physicians later came to notice that the drug had several immunosuppressive and antiproliferative properties. The drug was then abandoned for use as an anti-fungal agent.What makes Rapamycin different from many drugs is the fact that it has immunosuppressant properties. Unlike other anti-rejection drugs that tend to have adverse side effects over a period of time on the kidneys, Rapamycin displays lower toxicity levels towards the kidneys. For patients who suffer from the hemolytic-uremic syndrome, having a kidney transplant is normally the lasting solution. When having this transplant, there are normally high risks of contracting the same diseases due to use of calcineurin inhibitors. Using Rapamycin reduces the chances of contracting the disease for a second-time due to its low toxicity levels towards the kidneys.

Rapamycin can be used in the treatment of Lymphangioleiomyomatosis as it is known to block the gateway that brings about the Lymphangiogenic development factors. When Rapamycin is taken in the right doses, it is known to enhance the immune response system towards tumors and promote the regression of the tumor. Facial angiofibromas can also be cured using Rapamycin creams, ointments or gels.The use of Sirolimus is known to reduce brain lesions and prevent mental defects in mice. This means that it may be a possible cure for Alzheimer’s disease. Further tests on mice showed that administering nanoparticles coated in Rapamycin results to an increased grip strength of about 30%. This means that Rapamycin may be used to cure Muscular Dystrophy. Currently, there is some research that is in progress regarding Systemic Lupus Erythematosus treatment. Since Sirolimus blocks stimulation of mTORC1, this means that mTORC2 ends up getting suppressed. Research shows that Rapamycin reversed the stimulation of mTORC1 in mice. These findings are a positive step towards finding the right cure to the disease in humans.

Dr. Mikhail Blagosklonny continues to conduct research on various treatments procedures. His ambition is to come up with a treatment for cancer in a cost-effective way. He hopes that his findings will inspire other researchers to pick up from where he will leave off. Mikhail is focused on finding out ways in which cancer cells can be eliminated from the human body without having to destroy the normal cells that are crucial in the recovery of the mind and body. These cells are currently damaged after continuous cancer treatment.Dr. Mikhail Blagosklonny is a professor at the Rosewell Park Cancer Institute, which is in Buffalo, New York. His focus is on Oncology. He has done several research projects on cancer and different cancer therapies. Mikhail is also Oncortarget’s Editor-in-Chief. At Oncortarget, Mikhail has published extensive research regarding aging. He advocates for the use of Rapamycin to increase human beings’ lifespan with immense and unparalleled contributions. Mikhail gets inspiration from his peers and students who take a keen interest in wanting to continue to expand on his research.

Comments are closed, but trackbacks and pingbacks are open.